Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery, results from the ETHOS registry

Thrombosis and Haemostasis

Volumn 107, Issue 2, 2012, Pages 280-287

  Bergqvist, David ^a   Arcelus, Juan I ^b   Felicissimo, Paulo ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL FERNANDO FONSECA   (Portugal)

Author keywords

Compliance; ETHOS registry; Orthopaedic surgery; Post discharge venous thromboembolism prophylaxis

Indexed keywords

ANTIVITAMIN K; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; FEMALE; HIGH RISK PATIENT; HIP ARTHROPLASTY; HIP FRACTURE; HOSPITAL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; WARD;

ADULT; AGED; ANTICOAGULANTS; COST OF ILLNESS; DRUG UTILIZATION REVIEW; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PATIENT COMPLIANCE; PATIENT DISCHARGE; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RISK; VENOUS THROMBOEMBOLISM;

EID: 84856627774     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th11-07-0464     Document Type: Article

References (24)

1. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
2. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
3. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228.
4. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001; 83-A: 336-345.
5. Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin Ther 2009; 31: 1129-1141.
6. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecularweight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135: 858-869.
7. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
8. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 155-171.
9. Sackett DL, Haynes RB, Gibson ES, et al. Patient compliance with antihypertensive regimens. Patient Couns Health Educ 1978; 1: 18-21.
10. Rudd P. Compliance with antihypertensive therapy: raising the bar of expectations. Am J Manag Care 1998; 4: 957-966.
11. Larsen J, Stovring H, Kragstrup J, et al. Can differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2. BMC Public Health 2009; 9: 145.
12. Watts AC, Howie CR, Simpson AH. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Br 2006; 88: 107-110.
13. Colwell CW, Jr., Pulido P, Hardwick ME, et al. Patient compliance with outpatient prophylaxis: an observational study. Orthopedics 2005; 28: 143-147.
14. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 338S-400S.
15. Bergqvist D, Arcelus JI, Felicissimo P. Evaluation of duration of thromboembolic prophylaxis after major orthopedic surgery: the ETHOS registry. J Thromb Haemost. 2009; 7 (Suppl 2): Abstract OC-TU-019.
16. Bergqvist D, Arcelus JI, Felicissimo P, ETHOS Investigators. Evaluation of the duration of thromboembolic prophylaxis after high-risk orthopaedic surgery: The ETHOS observational study. Thromb Haemost 2012; 107: 270-279.
17. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.
18. Horne R, Cooper V, Fisher M. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives. AIDS Care 2008; 20: 1029-1038.
19. Horne R, Kovacs C, Katlama C, et al. Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? AIDS Res Ther 2009; 6: 2.
20. Guijarro R, Montes J, San Román C, et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011; 105: 610-615.
21. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: A case-control study. Am J Med 1997; 103: 11-17.
22. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185-191.
23. Herlitz J, Tóth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010; 10: 125-141.
24. Platt AB, Localio AR, Brensinger CM, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008; 17: 853-860.